Analysis of side effect in thyroid cancer patients received combined treatment with radioiodine and external beam radiotherapy

«Radiation and Risk», 2021, vol. 30, No. 4, pp.40-51

DOI: 10.21870/0131-3878-2021-30-4-40-51

Authors

Khvostunov I.K. – Head of Lab., D. Sc., Biol. Contacts: 4 Korolyov str., Obninsk, Kaluga region, Russia, 249035. Tel: (484) 399-73-92; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. .
Krylov V.V. – Head of Dep., MD
Rodichev A.A. – Oncologist, C. Sc., Med.
Shepel N.N. – Senior Researcher, C. Sc., Biol.
Korovchuk O.N. – Researcher
Kochetova T.Yu. – Researcher
Khvostunova T.I. – Researcher
Zhironkina A.S. – Researcher. A. Tsyb MRRC.
A. Tsyb MRRC, Obninsk

Abstract

Radical surgery is the mainstay for differentiated thyroid cancer, radioiodine therapy followed by the surgery is the “gold standard” treatment modality indicated after the surgery. Radioiodine therapy becomes practically non-alternative treatment for patients with distant metastases. However, orally administered radioiodine may be also absorbed into the bloodstream and can damage surrounding normal organs and tissues and cause side effect. To test radioiodine therapy safety side effects of the radionuclide on somatic cells should be accurately assessed. In addition, external beam radio-therapy can also damage adjacent normal organs and tissues and thereby increases radioiodine therapy side effect. It is possible to evaluate patient-specific total radiation dose with the use of cyto-genetic assay of chromosome aberrations level in peripheral blood lymphocytes because some types of chromosome aberrations are specific radiation markers clearly indicating that the cells have been exposed to radiation. Radiation absorbed dose can be estimated by the number of the aberrations occurrence frequency, and the value of side radiation dose greatly depends on a patient personality. In this case peripheral blood lymphocytes are thought of as a model of somatic and bone marrow cells. The paper present results of application of cytogenetic assay for estimating side effects caused by exposure of adjacent organs and tissues to external beam radiotherapy and surrounding somatic cells to radioiodine therapy. Results of statistical analysis of external beam radiotherapy related side effect contribution to the total side effect are present in the paper. The joint group of 43 patients was involved in the study, all patients received radioiodine therapy and 5 of them received also external beam radiotherapy in addition to radioiodine therapy. All patents received radioiodine therapy in the Radionuclide Therapy Department, A. Tsyb MRRC in Obninsk. Cytogenetic assay was carried out in the Radiation Cytogenetics Laboratory, A. Tsyb MRRC. Results of the study and ex-amination of regularities of radioiodine therapy and external beam radiotherapy related side effects development make it evident that patients received combining radioiodine therapy and external beam radiotherapy should present special group with the treatment plan different from that for the radioio-dine therapy exposed group. Exposure to external radiation may cause not only significant overesti-mation but also a false-positive underestimation of the number of radiation-specific markers because of lymphocytes inhibition following exposure to high total radiation dose. Inhibition effect may be a result of overestimating multiple radioiodine therapy administrations to achieve total ¹³¹I activity (Σact) exceeds 1200 mCi. The absolute value of the total focal radiotherapy dose is probably irrelevant. In general, patients assigned to both radioiodine therapy and external beam radiotherapy require personalized approach to treatment.

Key words
radioiodine therapy, external beam radiotherapy, radiopharmaceutical, radioiodine, side dose, chromosomal aberrations, blood lymphocytes.

References

1. Paltsev M.A., Belushkina N.N., Chaban E.A. 4P-medicine as a new model of healthcare. Zhurnal ORGZDRAV: novosti, mneniya, obuchenie – Journal of Health Organization: news, opinions, training, 2015, vol. 2, no. 2, pp. 48-55. (In Russian).

2. Mikhel I.V. Philosophical essays on 4P-medicine, bioethics and the future of man. Saratov, Sarat. gos. tekhn. universitet, 2016. 208 p. (In Russian).

3. Khvostunov I.K., Saenko V.A., Krylov V.V., Rodichev A.A., Yamashita S. Cytogenetic biodosimetry and dose-rate effect after radioiodine therapy for thyroid cancer. Radiat. Environ. Biophys., 2017, vol. 56, no. 3, pp. 213-226.

4. Stolbovoy A.V., Zalyalov I.F. Radiobiology models and clinical radiation oncology. Onkologiya. Zhurnal im. P.A. Gertsena – P.A. Herzen Oncology Journal, 2016, vol. 6, pp. 88-96. (In Russian).

5. Robbins R.J., Schlumberger M.J. The evolving role of 131I for the treatment of differentiated thyroid carcinoma. J. Nucl. Med, 2005, vol. 46, no. 1 Suppl., pp. 28S-37S.

6. Dorn R., Kopp J., Vogt H., Heidenreich P., Carroll R.G., Gulec S.A. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J. Nucl. Med, 2003, vol. 44, no. 3, pp. 451-456.

7. Rodichev A.A., Garbuzov P.I., Drozdovsky B.Ya., Krylov V.V., Guseva T.N., Davydov G.A., Parshin V.S., Ilyin A.A., Chebotareva I.V. Twenty-year experience of radioiodine therapy of distant metastases of differen-tiated thyroid cancer in children and adolescents. Vestnik RONTs im. N.N. Blokhina RAMN – Journal of N.N. Blokhin Russian Cancer Research Center RAMS, 2009, vol. 20, no. S2, pp. 19-20. (In Russian).

8. Khvostunov I.K., Krylov V.V., Rodichev A.A., Shepel N.N., Korovchuk O.N., Kochetova T.Yu., Pyatenko V.S., Khvostunova T.I. Assessment of the adverse radiation effect of radioiodine therapy for children and adolescents based on cytogenetic examination. Abstracts of the VII Congress of Pediatric Oncologists of Rus-sia with international participation "Achievements and prospects of pediatric oncology", Moscow, October 25-26, 2018. Prilozhenie k Zhurnalu Onkopediatriya – Supplement to the Journal Oncopediatrics, 2018, vol. 5, no. 3, pp. 15. (In Russian).

9. Holst J.P., Burman K.D., Atkins F., Umans J.G., Jonklaas J. Radioiodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis. Thyroid, 2005, vol.15, no. 12, pp. 1321-1331.

10. Krylov V.V., Garbuzov P.I., Kochetova T.Yu., Shurinov A.Yu., Borodavina E.V. Therapeutic radiology. National leadership. Chapter 34. Radionuclide therapy. Eds.: A.D. Kaprin, Yu.S. Mardynskiy. Moscow, GEOTAR-Media, 2018, pp. 637-665. (In Russian).

11. Brill A.B., Stabin M., Bouville A., Ron E. Normal organ radiation dosimetry and associated uncertainties in nuclear medicine, with emphasis on iodine-131. Radiat. Res., 2006, vol. 166, no. 1, pp. 128-140.

12. Van Nostrand D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid, 2009, vol. 19, no. 12, pp. 1381-1391.

13. Haenscheid H., Lassmann M., Luster M., Thomas S.R., Pacini F., Ceccarelli C., Ladenson P.W., Wahl R.L., Schlumberger M., Ricard M., Driedger A., Kloos R.T., Sherman S.I., Haugen B.R., Carriere V., Corone C., Reiners C. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J. Nucl. Med., 2006, vol. 47, no. 4, pp. 648-654.

14. Kulkarni K., Van Nostrand D., Atkins F.B., Aiken M., Burman K., Wartofsky L. The frequency with which empiric amounts of radioiodine “over-“ or “under-“ treat patients with metastatic well-differentiated thyroid cancer. Thyroid, 2006, vol. 16, no. 1, pp. 1-5.

15. Stabin M.G., Sharkey R.M., Siegel J.A. RADAR commentary: Evolution and current status of dosimetry in nuclear medicine. J. Nucl. Med., 2011, vol. 52, no. 7, pp. 1156-1161.

16. Luster M., Clarke S.E., Dietlein M., Lassmann M., Lind P., Oyen W.J.G., Tennvall J., Bombardieri E. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur. J. Nucl. Med. Mol. Imaging, 2008, vol. 35, no. 10, pp. 1941-1959.

17. Verburg F.A., Lassmann M., Mäder U., Luster M., Reiners C., Hänscheid H. The absorbed dose to the blood is a better predictor of ablation success than the administered 131-I activity in thyroid cancer patients. Eur. J. Nucl. Med. Mol. Imaging, 2011, vol. 38, no. 4, pp. 673-680.

18. Cytogenetic analysis for radiation dose assessment: a manual. Technical Reports Series No. 405. Vienna, IAEA, 2001. 127 p.

19. Khvostunov I.K., Krylov V.V., Rodichev A.A., Shepel N.N., Korovchuk O.N., Kochetova T.Yu., Khvostunova T.I., Zhironkina A.S. The significance of clinic-diagnostic factors in the course of estimation of side exposure of differentiated thyroid cancer patients after radioiodine therapy. Radiatsiya i risk – Radiation and Risk, 2021, vol. 30, no. 2, pp. 101-112.

Full-text article (in Russian)